en · de · es · pt
handling-notes.peptides5388.com › Data › Bremelanotide Identity And Background — Practical Notes

Bremelanotide Identity And Background — Practical Notes

By Editorial Desk · published 2025-08-27 · last reviewed 2025-10-19 · Data

If you have been reading about half-life and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Updated 2025-10-19. Numbers and descriptions here follow the published literature rather than marketing material.

Bremelanotide Identity and Background

Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.

The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.

Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.

Peptide Handling and Storage Practice

Reverse-phase high-performance liquid chromatography is the standard method for assessing purity. Mass spectrometry confirms molecular identity and detects sequence variants or truncation products. Ultraviolet absorbance at 214 or 280 nm is used for quantification, with the choice depending on the peptide sequence. Method validation typically addresses linearity, limit of detection, and precision across a defined concentration range. Impurity profiling may also employ ion-exchange or size-exclusion chromatography, and these techniques complement one another.

Certificate of analysis documents usually report purity percentage, molecular weight, and appearance. Researchers verify identity by comparing observed and theoretical mass values. Chain-of-custody records and batch numbers help trace material from source to experiment. Independent verification of supplier claims is considered good practice when material identity is critical to a study. Records should include the storage history of each aliquot, and unexpected deviations in appearance or solubility warrant re-testing before use.

Lyophilized peptide material is generally stored at -20 °C or below to limit degradation, while reconstituted solutions are less stable and are typically kept refrigerated and protected from light. Repeated freeze-thaw cycles can accelerate aggregation and should be minimized. Stability for any specific lot depends on purity, moisture content, and packaging. Handling in a temperature-controlled environment reduces variability across replicates, and exposure to ambient humidity during weighing can introduce error. Aliquotting reduces the number of times a stock container is opened.

Pt-141 at a glance

PropertyValueNotes
Molecular formulaC50H68N14O10Cyclic heptapeptide backbone
Molecular massApproximately 1025 DaNominal mass of the free peptide
AppearanceWhite to off-white lyophilised powderTypical for purified synthetic peptides
Solubility classFreely soluble in waterOrganic solubility is limited
Typical storage temperature−20 °C or belowProtect from moisture and light

Receptor Mechanism And Pharmacokinetics

The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.

After subcutaneous dosing, peak plasma concentrations appear within roughly one hour, and elimination is fast, with a half-life on the order of a few hours. Degradation is mainly proteolytic, and at least one circulating fragment retains receptor activity, so parent-drug levels alone do not describe total exposure. Clearance does not depend heavily on hepatic cytochrome enzymes, which lowers the likelihood of common metabolic interaction routes. Data in renal or hepatic impairment are limited. Repeated dosing does not appear to produce marked accumulation given the short half-life.

Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.

Related pages on this site

Development History And Regulatory Status

Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.

Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.

PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.

Further detail

During his 1927 Arctic trip with A. Y. Jackson, Banting realized that crew or passengers on board the Hudson's Bay Company (HBC) paddle wheeler SS Distributor were responsible for spreading the influenza virus down the Slave River and Mackenzie River, a virus that had over the summer and autumn spread territory-wide, devastating the aboriginal population of the north. Returning from the trip, Banting gave an interview in Montreal with a Toronto Star reporter under the agreement that his statements on HBC would remain off the record. The conversation was nonetheless published in the Toronto Star and rapidly reached a wide audience across Europe and Australia. Banting was angry at the leak, having promised the Department of the Interior not to make any statements to the press prior to clearing them. The article noted that Banting had given the journalist C. R. Greenaway repeated instances of how the fox fur trade always favoured the company: "For over $100,000 of fox skins, he estimated that the Eskimos had not received $5,000 worth of goods." He traced this treatment to health, consistent with reports made in previous years by RCMP officers, suggesting that "the result was a diet of 'flour, biscuits, tea and tobacco,' with the skins that once were used for clothing traded merely for 'cheap whiteman's goods.'" The fur trade commissioner for the Hudson's Bay Company called Banting's remarks "false and slanderous", and a month later, the governor and general manager of HBC met Banting at the King Edward Hotel to demand a retraction.

==== Copper ==== The antimicrobial mechanisms of copper have been studied for decades and are still under investigation. A summary of potential mechanisms is available here: Antimicrobial properties of copper#Mechanisms of antibacterial action of copper. Researchers today believe that the most important mechanisms include the following:

=== War in Yemen (2014–present) === Yemen was riven in 2015, with the Houthis establishing a new government in Sanaa and Hadi retreating with his supporters to Aden, and later Saudi Arabia. The Arab League, led by the Saudis, began a bombing campaign and mobilization of various armed forces in the region for a possible invasion.

==== Other ==== People taking zinc supplements may slow down the progress to age-related macular degeneration. Zinc supplement is an effective treatment for acrodermatitis enteropathica, a genetic disorder affecting zinc absorption that was previously fatal to affected infants. Zinc deficiency has been associated with major depressive disorder (MDD), and zinc supplements may be an effective treatment. Zinc may help individuals sleep more.

Sources: en.wikipedia.org

Supporting material

== Function == Laminins form independent networks and are associated with type IV collagen networks via entactin, fibronectin, and perlecan. The proteins also bind to cell membranes through integrins and other plasma membrane molecules, such as the dystroglycan glycoprotein complex and Lutheran blood group glycoprotein. Through these interactions, laminins critically contribute to cell attachment and differentiation, cell shape and movement, maintenance of tissue phenotype, and promotion of tissue survival. Some of these biological functions of laminin have been associated with specific amino-acid sequences or fragments of laminin. For example, the peptide sequence [GTFALRGDNGDNGQ], which is located on the alpha-chain of laminin, promotes the adhesion of endothelial cells. Laminin alpha4 is distributed in a variety of tissues, including peripheral nerves, dorsal root ganglion, skeletal muscle, and capillaries; in the neuromuscular junction, it is required for synaptic specialisation. The structure of the laminin-G domain has been predicted to resemble that of pentraxin.

intensive property A physical quantity whose value does not depend on the size of the system or the quantity of matter for which it is measured. Examples include density, temperature, and pressure. Contrast extensive property.

In the late 18th century, American settlers began to expand westward in larger numbers, many with a sense of manifest destiny. The Louisiana Purchase of 1803 from France nearly doubled the territory of the United States. Lingering issues with Britain remained, leading to the War of 1812, which was fought to a draw. Spain ceded Florida and its Gulf Coast territory in 1819. The Missouri Compromise of 1820, which admitted Missouri as a slave state and Maine as a free state, attempted to balance the desire of northern states to prevent the expansion of slavery into new territories with that of southern states to extend it there. Primarily, the compromise prohibited slavery in all other lands of the Louisiana Purchase north of the 36°30′ parallel. As Americans expanded further into territory inhabited by Native Americans, the federal government implemented policies of Indian removal or assimilation. The most significant such legislation was the Indian Removal Act of 1830, a key policy of President Andrew Jackson. It resulted in the Trail of Tears (1830–1850), in which an estimated 60,000 Native Americans living east of the Mississippi River were forcibly removed and displaced to lands far to the west, causing 13,200 to 16,700 deaths along the forced march. Settler expansion as well as this influx of Indigenous peoples from the East resulted in the American Indian Wars west of the Mississippi.

Sources: en.wikipedia.org

Frequently asked questions

What class of compound is this?

It is a synthetic cyclic peptide that acts as an agonist at melanocortin receptors. It is not a hormone replacement therapy and not a vasodilator in the usual clinical sense, although it does affect vascular tone. Chemically it belongs to the melanocortin analogue family.

Why does the code PT-141 still appear?

PT-141 was the internal development code used during early research and it persists in older publications, conference abstracts, and informal listings. The code and the approved name refer to the same molecule. Its continued use reflects habit in the literature rather than any difference in substance.

Is intranasal use equivalent to approved use?

No. The intranasal form was studied in trials but was never approved, and absorption through the nasal route varies considerably between individuals. Approved labelling covers a subcutaneous injection only. Any nasal product sold outside regulated channels falls outside verified manufacturing.

How should a lyophilized peptide be stored?

Storage at -20 °C or below is standard for long-term stability. Desiccant and sealed containers limit moisture exposure. Solutions are prepared only when needed.

Network